Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2023 Nov 30;12(11):2359-2365.
doi: 10.21037/tlcr-23-470. Epub 2023 Nov 1.

The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer

Ivy Riano  1 , Konstantin H Dragnev  1 , Joseph D Phillips  2
Affiliations
Editorial

The beginning of the perioperative immunotherapy era in early-stage non-small cell lung cancer

Ivy Riano et al. Transl Lung Cancer Res. .
No abstract available

Keywords: Early-stage lung cancer; immune checkpoint inhibitor (ICI); immunotherapy; perioperative therapy.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-23-470/coif). K.H.D. is a consultant/advisor for Merck, Roche/Genentech, Eli Lilly and Novartis. J.D.P. received a research grant from KSQ Therapeutics, Inc., and he is an unpaid member of the Board of Directors of the non-profit Thoracic Surgery Outcomes Research Network. IR has no conflicts of interest to declare.

Comment on

  • Perioperative Pembrolizumab for Early-Stage Non-Small-Cell Lung Cancer.
    Wakelee H, Liberman M, Kato T, Tsuboi M, Lee SH, Gao S, Chen KN, Dooms C, Majem M, Eigendorff E, Martinengo GL, Bylicki O, Rodríguez-Abreu D, Chaft JE, Novello S, Yang J, Keller SM, Samkari A, Spicer JD; KEYNOTE-671 Investigators. Wakelee H, et al. N Engl J Med. 2023 Aug 10;389(6):491-503. doi: 10.1056/NEJMoa2302983. Epub 2023 Jun 3. N Engl J Med. 2023. PMID: 37272513 Free PMC article. Clinical Trial.

References

    1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med 2018;378:2078-92. 10.1056/NEJMoa1801005 - DOI - PubMed
    1. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med 2018;379:2040-51. 10.1056/NEJMoa1810865 - DOI - PubMed
    1. Socinski MA, Jotte RM, Cappuzzo F, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med 2018;378:2288-301. 10.1056/NEJMoa1716948 - DOI - PubMed
    1. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med 2018;379:2342-50. 10.1056/NEJMoa1809697 - DOI - PubMed
    1. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. J Clin Oncol 2022;40:1301-11. 10.1200/JCO.21.01308 - DOI - PMC - PubMed